|
| Human IgG4 Fc Protein (LTP11022) |
|
| LTP11022 |
|
| 100ug |
|
|
$113 In stock |
| It is known as a IgG4-related disease and its differentiation is based on the analysis of IgG4 levels in the affected tissues. The IgG4-related disease is considered to be a generalized pathological process involving a wide spectrum of various disorders that may affect distant organs. |
| Recombinant Human IgG4 Fc Protein is expressed from Expi293 without tag. It contains Glu99-Gly326. |
|
| IgG4 Fc |
|
| Human |
|
| P01861 |
|
| Glu99-Gly326 |
|
| The protein has a predicted MW of 25.8 kDa. Due to glycosylation, the protein migrates to 30-35 kDa based on the Tris-Bis PAGE result. |
|
| The affinity constant of 1.365 uM as determined in SPR assay (Biacore T200). See testing image for detail. |
|
| No Tag |
|
| Expi293 |
|
| > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
|
|  |
